WASHINGTON — Federal regulators are intensifying their scrutiny of Diamond Shruumz, a popular brand of microdosing products, following a link to numerous illnesses and two potential deaths across the United States. The Food and Drug Administration (FDA) announced the brand’s comprehensive recall of its chocolate bars, infused cones, and gummy products, all of which are marketed as enhancing creativity and mental health benefits.
The probe escalates as adverse reports mount, with the FDA citing 74 illness cases spanning 28 states. Notably, 62 victims have sought medical attention with 38 requiring hospitalization due to severe symptoms. Authorities are particularly concerned about the two deaths currently under investigation, which may be associated with the brand’s offerings.
Diamond Shruumz, owned by Prophet Premium Blends, claims its products do not contain psychedelic substances. However, a recent study by the Centers for Disease Control and Prevention (CDC) detected psilocin, a controlled substance, in some of the company’s gummy products. This compound was found despite the products being labeled as containing Amanita muscaria, a legal yet psychoactive mushroom.
This discovery has led to significant backlash against the company, with recent hospital reports highlighting patient symptoms consistent with muscimol intoxication, a psychoactive compound found in Amanita muscaria. Symptoms reported include seizures, abnormal heart rates, and severe gastrointestinal distress.
The FDA’s initial warnings about the potential dangers of these products were first issued in June following preliminary investigations. Since then, the advisories have expanded as more severe adverse effects have been documented. The overarching concern is that the labels on these products may not accurately disclose their potent, and sometimes illegal, ingredients.
Consumers who have experienced adverse effects typically report severe symptoms shortly after ingestion, requiring urgent medical care. The FDA has cautioned that the total content of psychoactive substances in these products might vary significantly, leading to unpredictable and dangerous reactions.
The alarming rate of reported illnesses and the associated severe symptoms underline a growing public health concern regarding the loosely regulated market of microdosing products. These products are often sold with the promise of health benefits without sufficient regulatory oversight to ensure safety and efficacy.
As investigations continue, health authorities are urging consumers to remain vigilant. They advise against the use of products that claim psychedelic benefits or contain nootropic substances, as these can often misrepresent their actual contents and lead to severe health consequences. The ongoing recall is part of a broader effort to clamp down on misleading health products that pose significant risks to consumers.
The situation remains dynamic, with federal health officials promising to issue updates as new information becomes available. In the meantime, the public is encouraged to report any adverse effects from similar products to help aid the ongoing investigation and prevent further incidents.